FOLFIRINOX shows superior outcomes for locally advanced pancreatic cancer

Neoadjuvant therapy (NAT) with FOLFIRINOX significantly enhances resectability and overall survival (OS) in patients with locally advanced pancreatic cancer (LAPC). This umbrella review of nine systematic reviews highlights that FOLFIRINOX leads to higher R0 resection rates compared to gemcitabine/nab-paclitaxel, with improved OS. Furthermore, surgical resection post-NAT provides better survival outcomes than induction therapy alone. Cost-effectiveness analysis indicates that FOLFIRINOX, despite its higher cost, offers substantial OS benefits, making it a potential standard of care for LAPC.